AKRO Akero Therapeutics

Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference

Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference

SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024, at 5:00 p.m. P.T. in Las Vegas, NV.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at . Following the live webcast, an archived replay will be available on the Company's website.

About Akero Therapeutics

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in the ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in patients with compensated cirrhosis due to MASH (F4 fibrosis), as well as two ongoing Phase 3 clinical trials, the SYNCHRONY Histology study in patients with pre-cirrhotic MASH (F2-F3 fibrosis) and the SYNCHRONY Real-World study in patients with MASH (F1-F3 fibrosis) or MASLD. A third clinical trial, the SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH (F4 fibrosis), is expected to be initiated in the second quarter of 2024. The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4). Akero is headquartered in South San Francisco. Visit us at  and follow us on  and  for more information.

Investor Contact:

Christina Tartaglia

Stern Investor Relations, Inc.

212.362.1200

Media Contact:

Sarah O’Connell

732.456.0092



EN
08/05/2024

Underlying

AKROAkero Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Akero Therapeutics

 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics Reports First Quarter 2024 Financial Results and Pr...

Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update -- Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 -- -- Phase 3 SYNCHRONY Histology and SYNCHRONY Real-World studies in patients with pre-cirrhotic MASH (F2-F3) continue to enroll; SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH (F4) on track to be initiated in second quarter of 2024 -- SOUTH SAN FRANCISCO, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Akero Ther...

May 10, 2024 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics to Present at the BofA Securities 2024 Health Care ...

Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024, at 5:00 p.m. P.T. in Las Vegas, NV. A live webcast of the Company presentation will be available through the investor relations section of the C...

May 8, 2024 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced the appointment of Scott Gangloff as Chief Technology Officer. "I am delighted to welcome Scott to Akero. His depth of experience leading drug manufacturing for both national and multi-national biopharmaceutical organizations enriches our company with an invaluable perspective during the late...

April 30, 2024 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics Announces Closing of Public Offering of Common Stoc...

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares SOUTH SAN FRANCISCO, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a public offering price of $29.00 per share, which includes the exercise i...

March 8, 2024 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D...

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable to that of EFX alone and led to statistically significant improvements in non-invasive markers of liver injury and fibrosis and of metabolic health Results indicate potential of EFX to improve resolution of steatohepatitis and fibrosis for patients with MASH and type 2 diabetes already taking a GLP-1 receptor agonist SOUTH SAN FRANCISCO, Calif....

March 7, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch